Building BioTech Series - Episode 8

Building Biotech Series with Brent Cezairliyan

Published on: 

When it comes to biotech, both the academic and industry settings are crucial in developing novel medicines. Dr Brent Cezairliyan has experienced both sides of biotech, first through an academic career exploring bacterial pathogenesis, and now in his administrative role at Octagon Therapeutics. The company, headquartered in Cambridge, Massachusetts, focuses on autoimmune disease treatments. By developing targeted approaches to the inflammatory nature of the immune system, they hope their advances in biotech help future scientists navigate the field for years to come.